SIO GENE THERAPIES INC (SIOX) Stock News
NASDAQ:SIOX - Nasdaq - US8293991043 - Common Stock - Currency: USD
SIOX Latest News, Press Relases and Analysis
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. (
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively – Operating Cash Outflows for the Nine Months Ended December 31, 2022...
Recap: Sio Gene Therapies Q1 Earnings
Sio Gene Therapies (NASDAQ:SIOX) reported its Q1 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Sio Gene Therapies to dissolve company, liquidate assets (NASDAQ:SIOX)
The board of microcap Sio Gene Therapies (SIOX) has decided to dissolve the company and liquidate its assets following a review of potential strategic alternatives.
Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution
NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after...
Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results
- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively - Operating Cash Outflows for the Six Months Ended September 30, 2022...
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results
NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning! We're gearing up for another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday!
Sio Gene Therapies Provides Corporate Update
-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB...